[Interview Booklet] What Measurement Devices Accelerated Research in Regenerative Medicine Technology?
What is the measuring device that accelerated the research on direct reprogramming technology in regenerative medicine, which is highly anticipated?
Regenerative medicine is expected to become a treatment for diseases with high unmet medical needs. Among these, direct reprogramming technology can induce target cells from somatic cells without the use of pluripotent stem cells, potentially reducing both time and economic costs compared to conventional techniques. We spoke with Associate Professor Hideki Endo from Juntendo University Graduate School of Medicine, who is advancing research aimed at establishing regenerative treatment for type 1 diabetes patients through direct reprogramming, about this technology and the fully automated immunoassay system that has been key to its progress. Excerpt from the interview article: "If many researchers recognize that it can be used instead of conventional ELISA, and that it is simple and speedy, it could be utilized not only in regenerative medicine but also in other fields, leading to overall advancements in research." *The full text can be downloaded and viewed by clicking the "Download Catalog" button for the user interview article. For more details, please feel free to contact us.
Inquire About This Product
basic information
Please contact us.
Price range
Delivery Time
Applications/Examples of results
*You can view the detailed content of the article through the related link. For more information, please feel free to contact us.*
catalog（4）
Download All Catalogs![[Interview booklet] What measurement devices accelerated research in regenerative medicine technology?](https://image.mono.ipros.com/public/catalog/image/01/750/783646/IPROS3921757335968201992.jpeg?w=120&h=170)
![[Interview booklet] Quality control of cell manufacturing without human intervention through mechanization.](https://image.mono.ipros.com/public/catalog/image/01/b20/796125/IPROS5393216478718667743.jpeg?w=120&h=170)
![[Interview booklet] Achieving cardiac regenerative medicine through rapid protein measurement](https://image.mono.ipros.com/public/catalog/image/01/fe0/791417/IPROS15583398780106859010.jpeg?w=120&h=170)
Company information
Since its establishment in 1968, our company has been engaged in the field of specimen testing, focusing on the analysis of samples such as blood and urine, and currently supports the health of people in over 190 countries and regions. In the field of specimen testing, we have achieved a top-class market share in three areas: "Hematology," "Coagulation Testing," and "Urinalysis." We contribute to improving the quality of life (QOL) of people around the world in various scenes of their lifelong healthcare journey, and we aim to realize a rich health society through the optimization of medical care and healthcare costs.